Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 100 movers: Ocado gives back some gains; GSK rallies
(Sharecast News) - London's FTSE 100 was down 0.7% at 7,450.68 in afternoon trade on Friday. Online supermarket Ocado slid, having rocketed on Thursday amid speculation it could be takeover target for Amazon.
Housebuilders Persimmon, Berkeley, Taylor Wimpey and Barratt all fell amid concerns about the impact of surging borrowing costs.
GSK rallied after the pharmaceuticals group said that a Zantac trial that was due to begin next month in California was dismissed after a confidential settlement was agreed.
Danni Hewson, head of financial analysis at AJ Bell, said: "News pharmaceutical giant GSK has settled a case in California alleging its Zantac heartburn medication caused cancer, while crucially admitting no liability, is not a full stop on the saga but is the latest punctuation point in what shareholders will hope is its final stanza.
"Once the world's best-selling drug, there have been a series of lawsuits brought in the US implying a link between Zantac and cancer but, so far, GSK has been able to navigate its way through these choppy waters. A court ruling in Florida before Christmas, which provided a comprehensive dismissal of the plaintiffs' arguments, proved a bit of a lode star for the company.
"As it begins to put this issue behind it, focus will turn to its efforts to catch up with its close UK peer AstraZeneca which has drastically outperformed it in share price terms in recent years."
FTSE 100 - Risers
GSK (GSK) 1,420.20p 4.50% Convatec Group (CTEC) 211.80p 2.42% Croda International (CRDA) 5,566.00p 2.09% British American Tobacco (BATS) 2,620.00p 1.18% Pearson (PSON) 820.40p 1.16% Associated British Foods (ABF) 1,955.50p 0.98% Vodafone Group (VOD) 72.57p 0.93% Halma (HLMA) 2,252.00p 0.72% Severn Trent (SVT) 2,707.00p 0.71% National Grid (NG.) 1,042.50p 0.63%
FTSE 100 - Fallers
Ocado Group (OCDO) 526.00p -7.36% JD Sports Fashion (JD.) 141.95p -5.21% International Consolidated Airlines Group SA (CDI) (IAG) 159.65p -3.74% Smith (DS) (SMDS) 270.10p -3.67% Persimmon (PSN) 1,063.00p -3.67% Anglo American (AAL) 2,264.00p -2.87% Glencore (GLEN) 433.55p -2.79% Berkeley Group Holdings (The) (BKG) 3,765.00p -2.76% Taylor Wimpey (TW.) 100.00p -2.63% Barratt Developments (BDEV) 407.40p -2.61%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
